Logo image
Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection
Journal article   Open access   Peer reviewed

Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection

Andrew J. Sabers, Amber L. Williams and T. Michael Farley
BMJ case reports, Vol.13(10), p.e239210
10/01/2020
DOI: 10.1136/bcr-2020-239210
PMCID: PMC10577715
PMID: 33130588
url
https://doi.org/10.1136/bcr-2020-239210View
Published (Version of record) Open Access

Abstract

An 82-year-old man with an extensive medical history presented to the emergency room with complaints of generalised weakness and cough. He tested positive for COVID-19 10 days prior to presenting to the emergency room. Although his symptoms started a week prior to diagnosis, his weakness increased, warranting emergency response. A comprehensive metabolic panel was drawn from the patient on admission, indicating markedly high liver function tests (LFTs) >= 20 times above the upper limit of normal. On day 1 of admission, the decision was still made to start remdesivir (5-day course) due to decompensated acute respiratory failure as well as dexamethasone. The patient's LFTs significantly improved throughout his hospital stay. The patient made a full recovery and was discharged on day 10 of hospitalisation.
General & Internal Medicine Life Sciences & Biomedicine Medicine, General & Internal Science & Technology

Details

Metrics

Logo image